HEALTH TECHNOLOGY

Matrix Medical Network Announces Sale of Decentralized Clinical Trials Service Line to Emvenio Research

Matrix Medical Network | August 09, 2022 | Read time : 02:00 min

Matrix Medical

 Matrix Medical Network® and Emvenio Research® announced the sale of the Matrix Clinical Trials service line to Emvenio, a leading decentralized clinical trials company. The transaction will provide Emvenio with proven DCT capabilities, while allowing Matrix to focus on improving the health and wellness of health plan members, and keeping America's workers productive and safe, through its design of custom and flexible clinical solutions. Post transaction, Emvenio will deploy additional resources, technology, and capital to continue to grow and scale its clinical trials services both domestically and internationally, making clinical research more accessible, equitable, and effective.

"At the onset of the pandemic Matrix mobilized quickly to provide decentralized clinical trial solutions in support of vaccine and therapy development for COVID-19. We leveraged our skilled clinicians, Mobile Health Clinics, and experienced leaders to adapt traditional clinical trials protocols to better reach and recruit diverse, underserved, and high-risk patients. We are incredibly proud of the remarkable work the Matrix Clinical Trials team started during the pandemic and continued to expand upon. I am excited about this transition and look forward to watching the leaders and employees of Emvenio continue to develop and deliver decentralized clinical trial solutions that best serve those patients who most need access to new treatments."

Catherine J. Tabaka, Matrix Chief Executive Officer

"The leaders of Matrix Clinical Trials showed leadership, agility, creativity, and perseverance in building a decentralized clinical trial organization from the ground up," said Keith Henthorne, Emvenio Chief Executive Officer. "I look forward to working closely with these leaders in order to build upon this solid foundation established by Matrix and to continue making clinical trials more accessible to diverse populations throughout the world. To ensure continued access to clinical trials for the patients who need it most, many Matrix employees and leaders will be a part of the Emvenio team going forward. I am proud to be working alongside strong leaders like Dr. Daniel Castillo and Thad Wolfram, amongst others, and look forward to growing the company with them."

About Matrix Medical Network
Matrix Medical Network has provided expert care and health services to millions of at-risk individuals where they live and work for more than 20 years. The organization's network of approximately 4,000 clinicians meets individuals wherever they are, to assess their health and safety, identify and close care gaps, and offer life-changing services that activate them to manage their own health.

About Emvenio
Emvenio is a leading decentralized research organization (DRO) providing scalable and hybrid decentralized trial solutions with a focus on improving access and health equity in clinical research. Its mission is to eliminate the barriers to clinical trials by engaging with people in their communities and in their homes. Emvenio's technology enabled, innovative network of Mobile Research Sites, At Home Visits, and Virtual Visits are a unique blend of global DCT capabilities that can be deployed to better reach, recruit and retain diverse patient populations, while improving the clinical trial experience. These capabilities offer global DCT participant-centric approaches that provide flexibility, meet the most challenging clinical trial demands, and provide convenience for patients and caregivers in a compliant manner. Emvenio is transforming how all stakeholders engage in, experience, and deliver clinical research.

Spotlight

Dr Thomson talks about the causes and symptoms of chronic pain, how spinal cord stimulation works and the need for improvement in the treatment of chronic pain patients.

Spotlight

Dr Thomson talks about the causes and symptoms of chronic pain, how spinal cord stimulation works and the need for improvement in the treatment of chronic pain patients.

Related News

HEALTH TECHNOLOGY

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio

Axonics, Inc. | August 18, 2022

Axonics, Inc. a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology. The patents and allowed applications are part of Axonics’ patent portfolio and represents technology internally developed by the company covering a range of subject matter that includes the Axonics external trial system, tined lead, implantable neurostimulator, clinician programmer, wireless charging system and patient remote control. “Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence. The volume, subject matter diversity, and breadth of these patents demonstrate the investment in innovation that Axonics continues to make in sacral neuromodulation technology,” Raymond W. Cohen, chief executive officer About Axonics Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas. Axonics sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.

Read More

HEALTH TECHNOLOGY

Vicarious Surgical Announces Center of Excellence Agreements with HCA Healthcare and UH Ventures to Advance System Design

Vicarious Surgical Inc. | July 08, 2022

Vicarious Surgical Inc. a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it has signed collaborative Center of Excellence agreements with both HCA Healthcare, one of the nation’s leading providers of healthcare services comprising 182 hospitals, and University Hospitals Ventures, the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with more than 20 hospitals, over 50 health centers, and over 200 physician offices in northern Ohio. As part of these agreements, HCA Healthcare and UH Ventures will each provide user input through their system physicians as the Company advances the design of its Vicarious Surgical Robot. Through these distinct collaborations, Vicarious Surgical will gain unique exposure to the detailed surgical workflows at each of these partners and incorporate direct surgeon and administrator feedback into its total product ecosystem to meet the needs of major US hospital systems. Additionally, clinical and human-centered design experts from both HCA Healthcare and UH will assist Vicarious Surgical to further enhance product design, helping ensure readiness for streamlined adoption upon FDA Approval. “Establishing our Center of Excellence model with two leading U.S. health systems offers significant validation of our system’s in-hospital potential and creates an incredible opportunity to integrate real-world surgeon experiences and feedback as we work toward our system’s finalization. These partnerships establish two powerful innovation conduits through which our team gains unprecedented access to understanding and addressing the complexities of surgical workflow and hospital integration while building commercial expertise. Meanwhile, our clinical partners – HCA Healthcare and University Hospitals – become the first health systems to access our minimally invasive surgical robot and directly influence its advancement. We could not be more excited to partner with two of the top institutions in the country as we progress on our path to improve surgery for patients, surgeons, hospitals, and payors.” Adam Sachs, CEO and co-founder of Vicarious Surgical “Our surgical and innovation teams are on the cutting edge of new care technologies designed to benefit patients,” said Dr. Joseph Sabik, Chairman, Department of Surgery at University Hospitals. “Collaborating with Vicarious Surgical on their Center of Excellence model for training and next generation surgical robotics provides our team a thrilling front row seat in the quest to improve the landscape for minimally-invasive surgery that enhances patient care and clinical outcomes.” “University Hospitals’ goal is to be the most trusted health care partner in Northeast Ohio,” explained Kendra Gardiner, Director of Product Strategy for UH Ventures. “As part of this strategy, UH is dedicated to accelerating discovery, innovation and translation of scientific breakthroughs that address unmet clinical and social needs to enhance the lives of our patients, our communities and the world. We also aim to be the partner of choice by creating and sharing value together. This new relationship with Vicarious Surgical is one example of how we are advancing this objective.” About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. HCA Healthcare subsidiary Health Insight Capital makes equity investments in early-stage companies that are selected to provide innovative solutions for use in health system operations and is an investor in Vicarious Surgical. Please click here to connect with HCA Healthcare on social media. About UH Ventures UH Ventures is the innovation and commercialization arm of University Hospitals (UH), a comprehensive health system with annual revenues in excess of $5.0 billion, more than 20 hospitals, more than 50 health centers and outpatient facilities, and over 200 physician offices located throughout 16 counties. UH’s goal is to be the most trusted health care partner in Northeast Ohio and UH Ventures furthers this objective by shaping new products, services, experiences, and companies that improve the lives of patients and caregivers. To advance the UH mission, UH Ventures strives to support a diverse portfolio of value-adding opportunities in health care, enhance the distinct and unique capabilities of the system, and foster a culture of discovery, innovation, and entrepreneurship within UH and the larger community. For caregivers, UH Ventures provides the tools and resources needed to nurture, validate, and advance ideas sparked by day-to-day insights. For potential partners, UH Ventures seeks to be a dynamic living laboratory where both clinical and product insights can help accelerate emerging technologies tackling health care’s most pressing problems.

Read More

HEALTH TECHNOLOGY

McKesson Signs Agreement to Acquire Rx Savings Solutions

McKesson Corporation | September 20, 2022

McKesson Corporation announced that it has signed a definitive agreement to acquire Rx Savings Solutions a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers, reaching more than 17 million current patients. The transaction is valued up to $875 million, which includes a $600 million upfront payment and a maximum of $275 million of consideration contingent upon RxSS’ financial performance through calendar year 2025. The transaction is subject to customary closing conditions, including regulatory review, and is expected to close in the second half of Fiscal 2023. “Rx Savings Solutions’ offerings for employers and patients will strengthen McKesson’s ability to help solve the most common medication challenges related to access, affordability and adherence. We expect the acquisition of Rx Savings Solutions to accelerate McKesson’s growth priority in biopharma services by extending our ecosystem of differentiated medication access solutions to patients. Together with Rx Savings Solutions, McKesson will amplify our efforts to advance health outcomes for all.” Brian Tyler, chief executive officer, McKesson “This combination brings together two highly complementary organizations with closely aligned goals and values. By joining McKesson, we will be able to offer an exceptionally broad set of services to our clients and strengthen our leadership in prescription price transparency,” said Michael Rea, a clinical pharmacist who founded and currently leads Rx Savings Solutions. “This is a critical part of our growth journey, and we are excited about what the future holds for Rx Savings Solutions as part of McKesson.” RxSS contracts directly with health plans and large self-funded employers to maximize the effectiveness of benefit design to drive prescription cost savings for members. The company uses an evidence-based, proprietary machine-learning algorithm to help members understand available options for therapy and identify cost-effective prescription alternatives under their insurance. If a prescription change would benefit the member, RxSS provides assistance to update the prescription. The company also provides ongoing medication reminders to help improve adherence. Following the closing of the transaction, RxSS will become part of the company’s Prescription Technology Solutions business, which works across the healthcare delivery system to offer next-generation patient access, affordability and adherence solutions. The combined organization will endeavor to bring new capabilities for employers and patients to McKesson’s broad portfolio of pharmacy, provider, payer, and biopharma services. After initial integration, McKesson expects to use the combined medication access, affordability, and adherence services as a foundation to build new outcomes management programs for biopharma and payers, differentiated by their reach and efficacy at three touchpoints: provider office, pharmacy counter, and direct patient tools. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories. About Rx Savings Solutions Founded by pharmacist Michael Rea, Rx Savings Solutions helps members and payers reduce prescription drug costs through a combination of clinical technology, transparency, member engagement and concierge support. Currently 17 million members have access to personalized recommendations for lowering prescription costs and dedicated pharmacy experts to help navigate benefits, providers and pharmacies.

Read More